Hvsen Biotechnology Co., Ltd. (300871.SZ)
CNY 11.77
(-0.17%)
CNY 11.77
(-0.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.46 Billion CNY | 1.28% |
| 2022 | 1.44 Billion CNY | 28.93% |
| 2021 | 1.12 Billion CNY | 200.96% |
| 2020 | 373.07 Million CNY | 37.26% |
| 2019 | 271.79 Million CNY | 91.3% |
| 2018 | 142.08 Million CNY | 17.36% |
| 2017 | 121.06 Million CNY | 19.67% |
| 2016 | 101.15 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.48 Billion CNY | 2.76% |
| 2024 Q1 | 1.48 Billion CNY | 1.22% |
| 2024 Q2 | 1.44 Billion CNY | -2.36% |
| 2023 Q1 | 1.46 Billion CNY | 1.41% |
| 2023 FY | 1.46 Billion CNY | 1.28% |
| 2023 Q4 | 1.46 Billion CNY | 4.44% |
| 2023 Q3 | 1.4 Billion CNY | -4.32% |
| 2023 Q2 | 1.46 Billion CNY | -0.06% |
| 2022 Q4 | 1.44 Billion CNY | 19.5% |
| 2022 Q3 | 1.21 Billion CNY | 8.54% |
| 2022 Q2 | 1.11 Billion CNY | -1.67% |
| 2022 Q1 | 1.13 Billion CNY | 1.09% |
| 2022 FY | 1.44 Billion CNY | 28.93% |
| 2021 Q2 | 442.69 Million CNY | 28.04% |
| 2021 Q1 | 345.75 Million CNY | -7.32% |
| 2021 Q3 | 520.47 Million CNY | 17.57% |
| 2021 Q4 | 1.12 Billion CNY | 115.73% |
| 2021 FY | 1.12 Billion CNY | 200.96% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 373.07 Million CNY | 37.26% |
| 2020 Q4 | 373.07 Million CNY | -13.63% |
| 2020 Q3 | 431.94 Million CNY | 13.25% |
| 2020 Q2 | 381.41 Million CNY | 0.0% |
| 2019 Q2 | 190.37 Million CNY | 0.0% |
| 2019 Q4 | 271.79 Million CNY | 0.0% |
| 2019 FY | 271.79 Million CNY | 91.3% |
| 2018 FY | 142.08 Million CNY | 17.36% |
| 2017 FY | 121.06 Million CNY | 19.67% |
| 2016 FY | 101.15 Million CNY | 0.0% |